Conservest Capital Advisors’s VanEck Biotech ETF BBH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $3.81M | Buy |
20,276
+3,782
| +23% | +$729K | 0.35% | 35 |
|
|
2025
Q4 | $3.12M | Buy |
16,494
+1,243
| +8% | +$230K | 0.28% | 32 |
|
|
2025
Q3 | $2.53M | Sell |
15,251
-462
| -3% | -$75.3K | 0.23% | 36 |
|
|
2025
Q2 | $2.41M | Sell |
15,713
-1,716
| -10% | -$256K | 0.24% | 34 |
|
|
2025
Q1 | $2.74M | Sell |
17,429
-254
| -1% | -$41.2K | 0.29% | 32 |
|
|
2024
Q4 | $2.78M | Sell |
17,683
-548
| -3% | -$92.2K | 0.29% | 31 |
|
|
2024
Q3 | $3.03M | Hold |
18,231
| – | – | 0.31% | 34 |
|
|
2024
Q2 | $3.03M | Sell |
18,231
-723
| -4% | -$118K | 0.33% | 32 |
|
|
2024
Q1 | $3.15M | Sell |
18,954
-670
| -3% | -$111K | 0.32% | 33 |
|
|
2023
Q4 | $3.24M | Sell |
19,624
-486
| -2% | -$74.8K | 0.34% | 32 |
|
|
2023
Q3 | $3.13M | Sell |
20,110
-346
| -2% | -$55.3K | 0.38% | 27 |
|
|
2023
Q2 | $3.19M | Hold |
20,456
| – | – | 0.37% | 29 |
|
|
2023
Q1 | $3.32M | Buy |
20,456
+54
| +0.3% | +$8.74K | 0.4% | 27 |
|
|
2022
Q4 | $3.26M | Buy |
+20,402
| New | +$3.23M | 0.41% | 27 |
|
|
2022
Q3 | – | Sell |
-23,067
| Closed | -$3.49M | – | 23 |
|
|
2022
Q2 | $3.36M | Sell |
23,067
-5,796
| -20% | -$863K | 0.42% | 25 |
|
|
2022
Q1 | $4.68M | Buy |
28,863
+11,442
| +66% | +$1.85M | 0.52% | 24 |
|
|
2021
Q4 | $3.3M | Buy |
17,421
+7,325
| +73% | +$1.41M | 0.35% | 26 |
|
|
2021
Q3 | $2.04M | Hold |
10,096
| – | – | 0.23% | 32 |
|
|
2021
Q2 | $2.04M | Hold |
10,096
| – | – | 0.23% | 34 |
|
|
2021
Q1 | $1.77M | Buy |
10,096
+132
| +1% | +$23.9K | 0.2% | 32 |
|
|
2020
Q4 | $1.69M | Buy |
9,964
+987
| +11% | +$163K | 0.2% | 34 |
|
|
2020
Q3 | $1.46M | Hold |
8,977
| – | – | 0.2% | 33 |
|
|
2020
Q2 | $1.46M | Buy |
8,977
+23
| +0.3% | +$3.5K | 0.21% | 33 |
|
|
2020
Q1 | $1.15M | Sell |
8,954
-70
| -0.8% | -$9.43K | 0.19% | 34 |
|
|
2019
Q4 | $1.26M | Sell |
9,024
-31
| -0.3% | -$4.07K | 0.16% | 42 |
|
|
2019
Q3 | $1.07M | Sell |
9,055
-166
| -2% | -$20.6K | 0.15% | 45 |
|
|
2019
Q2 | $1.19M | Sell |
9,221
-676
| -7% | -$83.3K | 0.17% | 44 |
|
|
2019
Q1 | $1.27M | Hold |
9,897
| – | – | 0.19% | 44 |
|
|
2018
Q4 | $1.1M | Buy |
9,897
+1
| +0% | +$121 | 0.18% | 45 |
|
|
2018
Q3 | $1.35M | Sell |
9,896
-116
| -1% | -$15.1K | 0.2% | 41 |
|
|
2018
Q2 | $1.2M | Buy |
+10,012
| New | +$1.18M | 0.19% | 42 |
|
|
2017
Q4 | – | Sell |
-10,191
| Closed | -$1.37M | – | 85 |
|
|
2017
Q3 | $1.37M | Buy |
+10,191
| New | +$1.33M | 0.22% | 44 |
|
Other funds holding BBH
MIM
BFG
PPWM
Conservest Capital Advisors's BBH Position: Q1 2026 in Review
Conservest Capital Advisors increased its VanEck Biotech ETF (BBH) stake by 23% in Q1 2026, buying an estimated $729K and bringing the position to 20,276 shares worth $3.81M. The position accounts for 0.35% of the portfolio, ranked #35.
Conservest Capital Advisors first reported a position in BBH in Q3 2017 and has held it in 32 quarters since. The position peaked at $4.68M in Q1 2022. 112 funds tracked by Wall St. Rank hold BBH as of Q1 2026.
- Conservest Capital Advisors held 20,276 shares of VanEck Biotech ETF worth $3.81M as of Q1 2026.
- Conservest Capital Advisors bought 3,782 VanEck Biotech ETF shares in Q1 2026, an estimated $729K.
- VanEck Biotech ETF made up 0.35% of Conservest Capital Advisors's portfolio in Q1 2026, its #35 holding.
- Conservest Capital Advisors first reported a position in VanEck Biotech ETF in Q3 2017 and has held it in 32 quarters since.
- Conservest Capital Advisors's VanEck Biotech ETF position peaked at $4.68M in Q1 2022.
- 112 funds tracked by Wall St. Rank held VanEck Biotech ETF as of Q1 2026.
Based on Conservest Capital Advisors's 13F filing for Q1 2026, filed 4 May 2026.